Patient-reported outcomes of prostate high-dose-rate brachytherapy boost comparing an outpatient and inpatient protocol: A two-center chronologic cohort study

Chen, James Y.; Hruby, George; Stockler, Martin R.; Patanjali, Nitya; Bucci, Joseph; Pérez, G. Chacón; Loadsman, John A; Sheehan, Elizabeth M.

doi:10.1016/j.brachy.2011.03.002

Cited by 3 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Almost all of our patients now have their implants performed under regional rather than general anaesthesia. The effect of these changes on patient experience has been addressed in a separate publication 21 . Performing two separate implants has also been shown to eliminate the issue of inter‐fraction catheter displacement 22 …”

Section: Discussionmentioning

confidence: 99%

“…The effect of these changes on patient experience has been addressed in a separate publication. 21 Performing two separate implants has also been shown to eliminate the issue of inter-fraction catheter displacement. 22 Intra-fraction catheter displacement remains a concern, however, and as our protocol has developed, the insertion of fiducial markers has become standard.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

HDR brachytherapy combined with external beam radiation for localised prostate cancer: Early experience from the Sydney Cancer Centre

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

HDR brachytherapy combined with external beam radiation for localised prostate cancer: Early experience from the Sydney Cancer Centre

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…Access to operating rooms is limited, and there is the cost of disposables, including interstitial seeds. Finally, in the case of HDR brachytherapy, there may be patient discomfort and inconvenience 4 . There is also concern regarding increase in urinary toxicity, particularly urethral strictures, which may present late and be problematic 2, 5, 6…”

Section: Introductionmentioning

confidence: 99%

“…Finally, in the case of HDR brachytherapy, there may be patient discomfort and inconvenience. 4 There is also concern regarding increase in urinary toxicity, particularly urethral strictures, which may present late and be problematic. 2,5,6 External beam radiation therapy (EBRT) alternatives to brachytherapy in both prostate and cervical cancer have been proposed, but historically doses achieved have not been equivalent to those with brachytherapy.…”

Section: Introductionmentioning

confidence: 99%

Results of a Prospective Dose Escalation Study of Linear Accelerator–Based Virtual Brachytherapy (BOOSTER) for Prostate Cancer; Virtual HDR Brachytherapy for Prostate Cancer

Eade

Hruby

Booth

et al. 2019

Advances in Radiation Oncology

Self Cite

View full text Add to dashboard Cite

PurposeTo demonstrate feasibility and toxicity of linear accelerator–based stereotactic radiation therapy boost (SBRT) for prostate cancer, mimicking a high-dose-rate brachytherapy boost.Methods and MaterialsA phase 1 sequential dose escalation study of SBRT compared 20 Gy, 22 Gy, and 24 Gy to the prostate and 25 Gy, 27.5 Gy, and 30 Gy to the gross tumor volume in 2 fractions, combined with 46 Gy in 23 fractions of external beam radiation. Feasibility of dose escalation (volume receiving 125% and 150% of the dose) while meeting organ-at-risk dose constraints, grade 2 acute and late gastrointestinal and genitourinary toxicity, and freedom from biochemical failure were secondary endpoints.ResultsThirty-six men with intermediate- and high-risk prostate cancer were enrolled with a median follow-up of 24 months. Sixty-four percent of patients had high-risk features. Nine men were enrolled to dose level 1, 6 to level 2, and 6 to level 3. Another 15 patients were treated at dose level 3 on the continuation study. Dose level 3 achieved superior 125% (23.75 Gy) and 150% (28.5 Gy) dose compared to dose levels 1 and 2, with minimal differences in organ-at-risk doses. Kaplan-Meier estimate of freedom from biochemical failure at 3 years was 93.3%. There were no late grade 2 or 3 gastrointestinal events. The late grade 2 genitourinary toxicity at 2 years was 19.3%. Prostate-specific membrane antigen positron emission tomography was performed at 2 years with no local recurrences.ConclusionsWe have shown that a linear accelerator–based SBRT boost for prostate cancer is feasible and can achieve doses comparable to high-dose-rate boost up to the 150% isodose volumes. Rectal, bladder, and urethral doses remained low, and long-term toxicity was the same as or better than previous reports from high-dose-rate or low-dose-rate boost protocols.

show abstract

High-dose-rate brachytherapy boost for prostate cancer: Outcomes and genitourinary toxicity

et al. 2015

View full text Add to dashboard Cite

Patient-reported outcomes of prostate high-dose-rate brachytherapy boost comparing an outpatient and inpatient protocol: A two-center chronologic cohort study

Cited by 3 publications

References 14 publications

HDR brachytherapy combined with external beam radiation for localised prostate cancer: Early experience from the Sydney Cancer Centre

HDR brachytherapy combined with external beam radiation for localised prostate cancer: Early experience from the Sydney Cancer Centre

Results of a Prospective Dose Escalation Study of Linear Accelerator–Based Virtual Brachytherapy (BOOSTER) for Prostate Cancer; Virtual HDR Brachytherapy for Prostate Cancer

High-dose-rate brachytherapy boost for prostate cancer: Outcomes and genitourinary toxicity

Contact Info

Product

Resources

About